Drug Profile

HB 2198

Alternative Names: HB-2198

Latest Information Update: 14 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hinge Bio
Class
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Systemic lupus erythematosus

Most Recent Events

23 Jan 2025 Hinge Bio has patent protection for platform compositions of matter and methods for their synthesis and use (Hinge Bio pipeline, January 2025)
16 Jan 2025 Preclinical trials in Systemic lupus erythematosus in USA (unspecified route)
16 Jan 2025 Pharmacodynamics data from a preclinical studies in Systemic lupus erythematosus released by Hinge Bio

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com